{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:07:33Z","timestamp":1774379253323,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02231-z","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T07:02:37Z","timestamp":1699426957000},"page":"1295-1303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review"],"prefix":"10.1007","volume":"47","author":[{"given":"D.","family":"Z\u00fa\u00f1iga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-0972","authenticated-orcid":false,"given":"M. A. M.","family":"Stumpf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-7393","authenticated-orcid":false,"given":"A. L. S.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-6756","authenticated-orcid":false,"given":"A.","family":"Glezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"issue":"10","key":"2231_CR1","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jocn.2015.03.058","volume":"22","author":"A Wong","year":"2015","unstructured":"Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci Off J Neurosurg Soc Aust 22(10):1562\u20131567. https:\/\/doi.org\/10.1016\/j.jocn.2015.03.058","journal-title":"J Clin Neurosci Off J Neurosurg Soc Aust"},{"issue":"7","key":"2231_CR2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1210\/jcem.82.7.4088","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102\u20132107. https:\/\/doi.org\/10.1210\/jcem.82.7.4088","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2231_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","volume":"18","author":"A Tirosh","year":"2015","unstructured":"Tirosh A, Benbassat C, Lifshitz A, Shimon I (2015) Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18(1):108\u2013115. https:\/\/doi.org\/10.1007\/s11102-014-0563-z","journal-title":"Pituitary"},{"issue":"4","key":"2231_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s11102-009-0168-0","volume":"14","author":"LA Behan","year":"2011","unstructured":"Behan LA, Draman MS, Moran C et al (2011) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 14(4):362\u2013366. https:\/\/doi.org\/10.1007\/s11102-009-0168-0","journal-title":"Pituitary"},{"issue":"1","key":"2231_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109(1):42\u201350. https:\/\/doi.org\/10.1159\/000495775","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2231_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000156116","volume":"89","author":"VQ Passos","year":"2009","unstructured":"Passos VQ, Fortes MAHZ, Giannella-Neto D, Bronstein MD (2009) Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89(2):163\u2013170. https:\/\/doi.org\/10.1159\/000156116","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2231_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23(1):27\u201337. https:\/\/doi.org\/10.1007\/s11102-019-00987-3","journal-title":"Pituitary"},{"issue":"3","key":"2231_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117(3):421\u2013428. https:\/\/doi.org\/10.1007\/s11060-013-1270-8","journal-title":"J Neurooncol"},{"issue":"10","key":"2231_CR9","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1172\/JCI63937","volume":"122","author":"C Sonigo","year":"2012","unstructured":"Sonigo C, Bouilly J, Carr\u00e9 N et al (2012) Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest 122(10):3791\u20133795. https:\/\/doi.org\/10.1172\/JCI63937","journal-title":"J Clin Invest"},{"issue":"4","key":"2231_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704\u20131711. https:\/\/doi.org\/10.1210\/jc.2003-030979","journal-title":"J Clin Endocrinol Metab"},{"key":"2231_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","volume":"97","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH et al (2017) Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 97:595\u2013602. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.059","journal-title":"World Neurosurg"},{"issue":"3","key":"2231_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","volume":"39","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Mormando M et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288\u2013293. https:\/\/doi.org\/10.1007\/s12020-011-9462-5","journal-title":"Endocrine"},{"issue":"10","key":"2231_CR13","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2002-020426","volume":"87","author":"MP Gillam","year":"2002","unstructured":"Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87(10):4447\u20134451. https:\/\/doi.org\/10.1210\/jc.2002-020426","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2231_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","volume":"23","author":"V Bonert","year":"2020","unstructured":"Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary 23(3):307\u2013313. https:\/\/doi.org\/10.1007\/s11102-020-01039-x","journal-title":"Pituitary"},{"issue":"2","key":"2231_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jcem-64-2-391","volume":"64","author":"JC Prior","year":"1987","unstructured":"Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64(2):391\u2013394. https:\/\/doi.org\/10.1210\/jcem-64-2-391","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 2","key":"2231_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1258\/0004563053492784","volume":"42","author":"R Sodi","year":"2005","unstructured":"Sodi R, Fikri R, Diver M, Ranganath L, Vora J (2005) Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem 42(Pt 2):153\u2013159. https:\/\/doi.org\/10.1258\/0004563053492784","journal-title":"Ann Clin Biochem"},{"key":"2231_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2231_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/jcm12041437","volume":"12","author":"A Akirov","year":"2023","unstructured":"Akirov A, Rudman Y (2023) The role of aromatase inhibitors in male prolactinoma. J Clin Med 12(4):1437. https:\/\/doi.org\/10.3390\/jcm12041437","journal-title":"J Clin Med"},{"issue":"1","key":"2231_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/a:1022176631922","volume":"5","author":"J Carretero","year":"2002","unstructured":"Carretero J, Burks DJ, V\u00e1zquez G et al (2002) Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats. Pituitary 5(1):5\u201310. https:\/\/doi.org\/10.1023\/a:1022176631922","journal-title":"Pituitary"},{"key":"2231_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.steroids.2016.03.020","volume":"111","author":"MJ Garc\u00eda-Barrado","year":"2016","unstructured":"Garc\u00eda-Barrado MJ, Blanco EJ, Catalano-Iniesta L et al (2016) Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice. Steroids 111:121\u2013126. https:\/\/doi.org\/10.1016\/j.steroids.2016.03.020","journal-title":"Steroids"},{"issue":"3","key":"2231_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11102-012-0436-2","volume":"16","author":"H Akinci","year":"2013","unstructured":"Akinci H, Kapucu A, Dar KA et al (2013) Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior. Pituitary 16(3):386\u2013392. https:\/\/doi.org\/10.1007\/s11102-012-0436-2","journal-title":"Pituitary"},{"issue":"7","key":"2231_CR22","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1177\/0300060519848916","volume":"47","author":"YX Su","year":"2019","unstructured":"Su YX, Du GL, Shen HL et al (2019) Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women. J Int Med Res 47(7):3115\u20133126. https:\/\/doi.org\/10.1177\/0300060519848916","journal-title":"J Int Med Res"},{"issue":"6","key":"2231_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101403","volume":"9","author":"MJ Garc\u00eda Barrado","year":"2014","unstructured":"Garc\u00eda Barrado MJ, Blanco EJ, Carretero Hern\u00e1ndez M et al (2014) Local transformations of androgens into estradiol by aromatase P450 is involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells. PLoS ONE 9(6):e101403. https:\/\/doi.org\/10.1371\/journal.pone.0101403","journal-title":"PLoS ONE"},{"issue":"5","key":"2231_CR24","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1007\/s12035-023-03220-2","volume":"60","author":"A Selek","year":"2023","unstructured":"Selek A, Halbuto\u011fullar\u0131 ZSU, Aydemir \u00c7\u0130 et al (2023) Letrozole decreased testosterone-induced cell proliferation and prolactin secretion also increased apoptosis in MMQ and GH3 rat prolactinoma cell lines. Mol Neurobiol 60(5):2442\u20132454. https:\/\/doi.org\/10.1007\/s12035-023-03220-2","journal-title":"Mol Neurobiol"},{"issue":"6","key":"2231_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11102-021-01165-0","volume":"24","author":"F Ceccato","year":"2021","unstructured":"Ceccato F, Lizzul L, Voltan G, Barbot M, Scaroni C (2021) Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Pituitary 24(6):914\u2013921. https:\/\/doi.org\/10.1007\/s11102-021-01165-0","journal-title":"Pituitary"},{"issue":"3","key":"2231_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1210\/jcem-73-3-609","volume":"73","author":"JS Finkelstein","year":"1991","unstructured":"Finkelstein JS, Whitcomb RW, O\u2019Dea LS, Longcope C, Schoenfeld DA, Crowley WF (1991) Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73(3):609\u2013620. https:\/\/doi.org\/10.1210\/jcem-73-3-609","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2231_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1530\/EJE-09-0084","volume":"161","author":"RS Ribeiro","year":"2009","unstructured":"Ribeiro RS, Abucham J (2009) Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 161(1):163\u2013169. https:\/\/doi.org\/10.1530\/EJE-09-0084","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2231_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ygyno.2020.08.015","volume":"159","author":"SG Bell","year":"2020","unstructured":"Bell SG, Dalton L, McNeish BL et al (2020) Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. Gynecol Oncol 159(2):509\u2013514. https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.015","journal-title":"Gynecol Oncol"},{"key":"2231_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/165215","volume":"2015","author":"V Rochira","year":"2015","unstructured":"Rochira V, Kara E, Carani C (2015) The endocrine role of estrogens on human male skeleton. Int J Endocrinol 2015:165215. https:\/\/doi.org\/10.1155\/2015\/165215","journal-title":"Int J Endocrinol"},{"issue":"9453","key":"2231_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet Lond Engl 365(9453):60\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(04)17666-6","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"2231_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial. Ann Oncol 20(9):1489\u20131498. https:\/\/doi.org\/10.1093\/annonc\/mdp033","journal-title":"Ann Oncol"},{"issue":"12","key":"2231_CR32","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1210\/jc.2004-1717","volume":"89","author":"L Gennari","year":"2004","unstructured":"Gennari L, Nuti R, Bilezikian JP (2004) Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89(12):5898\u20135907. https:\/\/doi.org\/10.1210\/jc.2004-1717","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2231_CR33","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","volume":"369","author":"JS Finkelstein","year":"2013","unstructured":"Finkelstein JS, Lee H, Burnett-Bowie SAM et al (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369(11):1011\u20131022. https:\/\/doi.org\/10.1056\/NEJMoa1206168","journal-title":"N Engl J Med"},{"issue":"4","key":"2231_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1046\/j.1365-2265.1999.00849.x","volume":"51","author":"C Carani","year":"1999","unstructured":"Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR (1999) Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 51(4):517\u2013524. https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00849.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2231_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1530\/acta.0.1050167","volume":"105","author":"I Nicoletti","year":"1984","unstructured":"Nicoletti I, Filipponi P, Fedeli L, Ambrosi F, Gregorini G, Santeusanio F (1984) Testosterone-induced hyperprolactinaemia in a patient with a disturbance of hypothalamo-pituitary regulation. Acta Endocrinol (Copenh) 105(2):167\u2013172. https:\/\/doi.org\/10.1530\/acta.0.1050167","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"2","key":"2231_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11102-023-01313-8","volume":"26","author":"MAM Stumpf","year":"2023","unstructured":"Stumpf MAM, Pinheiro FMM, Silva GO et al (2023) How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary 26(2):187\u2013196. https:\/\/doi.org\/10.1007\/s11102-023-01313-8","journal-title":"Pituitary"},{"issue":"4","key":"2231_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4158\/EP10026.CR","volume":"16","author":"Z Heidari","year":"2010","unstructured":"Heidari Z, Hosseinpanah F, Shirazian N (2010) Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Pract 16(4):669\u2013672. https:\/\/doi.org\/10.4158\/EP10026.CR","journal-title":"Endocr Pract"}],"updated-by":[{"DOI":"10.1007\/s40618-023-02247-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02231-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02231-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02231-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:20:45Z","timestamp":1713770445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02231-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02231-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40618-023-02247-5","asserted-by":"object"}]},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40618-023-02247-5","URL":"https:\/\/doi.org\/10.1007\/s40618-023-02247-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study adhered to the principles outlined in the Declaration of Helsinki and received approval from the local Research Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written informed consent was obtained from each patient for publication of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}